OPEN-LABEL, NON-COMPARATIVE STUDY OF FK463 IN THE TREATMENT OF INVASIVE ASPERGILLOSIS.

计划入组 0 人

POSACONAZOLE (MK-5592) IV AND ORAL IN CHILDREN WITH INVASIVE ASPERGILLOSIS.

计划入组 0 人

A PROSPECTIVE, RANDOMIZED TRIAL COMPARING THE SAFETY, TOLERABILITY, AND EFFICACY OF VORICONAZOLE AND ANIDULAFUNGIN IN COMBINATION TO THAT OF VORICONAZOLE ALONE WHEN USED FOR PRIMARY THERAPY OF INVASIVE ASPERGILLOSIS IN PEDIATRIC SUBJECTS AGED 2 TO 17 YEARS

计划入组 0 人

AZD-4440

YZJ-2440

NN-4440

Engineered Bifidobacterium Shows Dual Promise: Oral Vaccine Boosts Anti-Tumor Immunity in Phase I Trial as NCI Funds Systemic Delivery Platform for Pancreatic Cancer

Scholar Rock's Stock Soars 440% Following Positive SAPPHIRE Trial Results

UK Faces Decision on $440 Million Palantir–NHS Data Contract as Break Clause Looms